What is PMOS?

What is PMOS?

Despite what the name suggests, Polyendocrine Metabolic Ovarian Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PMOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.

At its core, PMOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PMOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PMOS so challenging—and why understanding your unique experience matters.

So, how can the PMOS Association help?

We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PMOS—and make progress.

Here’s what you’ll find at PMOSA:

  • ✅ Reliable, science-backed information about what PMOS is (and isn’t)

  • 💬 Supportive communities of people who understand exactly what you’re going through

  • 🧬 Resources for navigating fertility, metabolic health, nutrition, and more

  • 🧠 Education for providers who want to better support their PMOS patients

  • 🙋‍♀️ Advocacy to make sure PMOS is recognized, researched, and respected

No fluff. No fad cures. Just real support, grounded in evidence and compassion.

At PMOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.

pcos

pcos: Latest results from PubMed

Development and Validation of the Shorter Versions of the Patient Care Ownership Scale for Use in Japan

CONCLUSIONS: This study suggests that the J-PCOS-8, J-PCOS-4, and J-PCOS-2 are low-burden, reliable, and valid scales for measuring PCO. These shorter versions may allow researchers to reduce questionnaire length, potentially resulting in higher response rates, improved completion rates, and better data quality, while enabling clinical educators to use them in daily educational initiatives.

Published on: Wed, 07 Oct 2026 06:00:00 -0400

Authors: Hirohisa Fujikawa, Kentaro Sakamaki, Hidetaka Tamune, Yuji Nishizaki, Hiroyuki Kobayashi, Yasuharu Tokuda,

Heart rate dynamics in polyendocrine metabolic ovarian syndrome: from heterogeneity to wearable digital phenotyping

Polyendocrine metabolic ovarian syndrome (PMOS) is the new consensus name for polycystic ovary syndrome (PCOS), emphasizing the broader multisystem nature of the condition. Altered autonomic nervous system (ANS) regulation may provide an integrative physiological perspective on the reproductive, metabolic, and cardiovascular alterations associated with PMOS/PCOS. Heart rate variability (HRV) provides a non-invasive approach for assessing autonomic regulation; however, conventional HRV indices...

Published on: Wed, 07 Oct 2026 06:00:00 -0400

Authors: Tingting Ye, Junran Wang, Xiaoai Guo, Xinyue Liu, Yankui Li, Qiaofeng Wu,

Serological Evaluation of Anti- FSH Antibody and Anti- LH antibody In Iraqi Women with Polycystic Ovarian Syndrome

CONCLUSION: Women with PCOS exhibit a significant decrease in anti-LH antibody levels along with variations in LH levels and LH/FSH ratio compared to healthy controls.

Published on: Wed, 07 Oct 2026 06:00:00 -0400

Authors: Hiba M Khaleel, Sura F Alsaffar,

Efficacy of ketogenic diet on glycemic-lipid metabolism and menstrual regularity in women with polycystic ovary syndrome: a randomized controlled trial

CONCLUSION: During the 12-week short-term intervention, the KD dietary intervention was superior to the SMD dietary intervention in improving insulin resistance and restoring menstrual regularity in women with PCOS. KD is suitable for acute metabolic intervention given its pronounced weight reduction and insulin sensitivity improvement; however, these findings were obtained in a single-center, exploratory trial and require validation in multi-center, larger-scale randomized controlled trials,...

Published on: Wed, 07 Oct 2026 06:00:00 -0400

Authors: Min Wang, Lingyun Xie, Ling Ma, Cuijun Zhang, Ya Wei, Yulu Wei, Yaru Li, Yang Xu, Jingjing Wang,

Early neuroendocrine signatures of polyendocrine metabolic ovarian syndrome risk: Pubertal programming, social brain signals, and novel therapeutic targets

Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is increasingly recognized as a disorder with developmental origins, yet its early neuroendocrine antecedents during puberty remain poorly understood. While most diagnostic frameworks apply post-menarche, growing evidence suggests that PMOS risk may be programmed well before clinical onset through alterations in central neuroendocrine pathways that emerge during the pubertal transition. In this...

Published on: Tue, 06 Oct 2026 06:00:00 -0400

Authors: Seda Hanife Oğuz, Bülent Okan Yildiz,

Ameliorative character of eugenol and propargylated eugenol against letrozole induced polycystic ovarian syndrome in in-vivo zebrafish model

Polycystic ovary syndrome (PCOS) is an endocrine condition that mainly affects female reproductive function and is often linked with metabolic disturbances. Letrozole (LET), though widely used for ovulation induction, may induce PCOS-like conditions with prolonged exposure. In this study, we evaluated the protective effect of eugenol (EU) and its derivative propargylated eugenol (PEU) against letrozole-induced PCOS using an in vivo zebrafish model. Molecular docking helped, that both compounds...

Published on: Tue, 06 Oct 2026 06:00:00 -0400

Authors: G Akash, Ali Oubella, S Vijaya Bharathi, Shine Kadaikunnan, Selvaraj Arokiyaraj, Mariadhas Valan Arasu, Bharath Kumar Chagaleti, Kathiravan Muthu Kumaradoss, Jesu Arockiaraj,

Jujuboside a Improves Polycystic Ovary Syndrome Through SIRT3-Mediated PINK1/Parkin-Dependent Mitochondrial Autophagy in Ovarian Granulosa Cells

Polycystic ovary syndrome (PCOS) is a common endocrine disorder, and its treatment remains a significant challenge. This study investigated the mechanism of Jujuboside A (JuA) in the treatment of PCOS through mitophagy. Granulosa cells (GCs) were collected from follicular fluid derived from PCOS women. The effects of JuA on PCOS were determined by measuring body weight, ovarian weight, estrous cycle, glucose level, insulin tolerance, and ovarian morphology in dehydroepiandrosterone-induced mice....

Published on: Tue, 06 Oct 2026 06:00:00 -0400

Authors: Nan Zhou, Jiahao Xu, Wenqiang Lv, Wei Tai, Guangyan Xie, Qing He, Ying Zhou, Nan Hu, Xueyan Zhou,

Insulin Resistance as a Potential Predictor of Post-Inflammatory Hyperpigmentation After CO2 Laser Resurfacing: A Real-World Study of a Dual Technique Protocol (Maghreb Experience)

CONCLUSION: The Dual Technique CO(2) laser protocol was associated with favorable clinical outcomes using relatively few treatment sessions. In this cohort, higher HOMA-IR was strongly associated with greater PIH severity, suggesting that insulin resistance may represent an additional factor associated with individual PIH susceptibility. These findings are hypothesis-generating and require confirmation in larger, controlled studies before metabolic assessment can be recommended for routine...

Published on: Tue, 06 Oct 2026 06:00:00 -0400

Authors: Sihem Benosman, Qiaofeng Zhao, Yuping Ran, Xueqin Huang, Alberto Leguina-Ruzzi,

From metabolic network to brain loop: unraveling the neuro-metabolic correlates in PCOS-related depression

CONCLUSION: Given the intricate neuro-metabolic correlates underlying PCOS-related depression, further studies were warranted and a synergistic therapeutic strategy of androgen suppression plus weight management might be considered.

Published on: Tue, 06 Oct 2026 06:00:00 -0400

Authors: Yi Cao, Zhaoying Li, Yuxing Zhang, Qian Wen, Yuanyuan Shi, Jing Xie, Dongfeng Zhang,

Foeniculum vulgare and metformin combination improve ovarian function in a rat model of polycystic ovary syndrome: targeting AMH imbalances, folliculogenesis disruption, fibrosis, and abnormal vascular density

Polycystic ovary syndrome (PCOS), a major cause of female infertility, is accompanied by elevated anti-Mullerian hormone (AMH), ovarian hypervascularity, and excessive collagen deposition. While metformin is a well-established treatment, no study has yet explored whether Foeniculum vulgare (Fennel)-a medicinal plant with documented anti-PCOS benefits, administered alone or in combination-can attenuate these hormonal and structural abnormalities; this study provides the first integrated...

Published on: Mon, 05 Oct 2026 06:00:00 -0400

Authors: Mahdiyeh Ahmadi, Fahimeh Pourjafari, Fatemeh Sheikhbahaei, Mahna Mansoori, Amir Asadi, Tahereh Haghpanah, Seyed Hassan Eftekhar-Vaghefi,

Functional Hypothalamic Amenorrhea Phenotype and Cardiovascular Disease Risk

CONCLUSIONS: FHA phenotype in mid-adulthood was associated with increased CHD risk independent of traditional risk factors. Menstrual history may serve as an early marker of cardiometabolic risk.

Published on: Mon, 05 Oct 2026 06:00:00 -0400

Authors: Chrisandra L Shufelt, Jennifer J Stuart, Jana Karam, Xiaoyu Che, JoAnn E Manson, Karen K Miller, Kathy Rexrode, Stephanie Faubion, Sarah Berga, C Noel Bairey Merz, Janet W Rich-Edwards,

Comparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Polyendocrine metabolic ovarian syndrome (PMOS), previously known by the name 'polycystic ovary syndrome (PCOS),' is a common and complex endocrine-metabolic disorder affecting approximately one in eight women. PMOS is increasingly regarded as a multisystem disorder rather than only a gynaecological condition. Exclusive of weight loss, metformin has been the mainstay pharmacological therapy in the treatment of PMOS; a new contender for the management of this condition is liraglutide. Liraglutide...

Published on: Mon, 05 Oct 2026 06:00:00 -0400

Authors: Indrajit Banerjee, Mooroogiah Krissheeven, Nishant Pandey, Shradha Banerjee, Jared Robinson, Indraneel Banerjee,

Gut dysbiosis, blood pressure regulation, and cardiometabolic risk in polyendocrine metabolic ovarian syndrome (PMOS)

Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is a common endocrine-metabolic disorder associated with increased hypertension and cardiometabolic risk. Gut dysbiosis is also frequently reported in affected women, raising the question of whether microbiome-linked pathways contribute to blood pressure elevation or vascular risk in this syndrome. To evaluate and synthesize the available evidence linking gut dysbiosis, gut microbial function,...

Published on: Sat, 03 Oct 2026 06:00:00 -0400

Authors: Muhammad Naveed, Tao Yang, Olivia Togliatti, Bina Joe, Jennifer W Hill,

Patient-derived prostate cancer organoids: model development, therapeutic applications, and challenges for precision oncology

Prostate cancer ranks among the most prevalent male malignancies worldwide, with castration-resistant prostate cancer (CRPC) and drug resistance representing major clinical challenges. Conventional preclinical models fail to faithfully recapitulate tumor heterogeneity and the tumor microenvironment (TME). Patient-derived prostate cancer organoids (PCOs) represent a promising 3D model that largely preserves the genomic, phenotypic, and functional signatures of primary tumors. Building on prior...

Published on: Sat, 03 Oct 2026 06:00:00 -0400

Authors: Jingzhen Zhu, Sheng Wang, Furong Du, Sihai Shao,

Metformin Use Before Assisted Reproductive Technology and Pregnancy Outcomes in Women With Polycystic Ovary Syndrome: A Nationwide Cohort Study

Metformin has been hypothesized to improve ovulation and pregnancy rates in women with polycystic ovary syndrome (PCOS) undergoing assisted reproductive technology (ART). This population-based cohort study assessed pregnancy outcomes associated with metformin use prior to ART in women with PCOS. We included 10,178 women with PCOS undergoing their first fresh embryo transfer cycle under the national health insurance program of South Korea between 2017 and 2021. Women who received metformin for...

Published on: Sat, 03 Oct 2026 06:00:00 -0400

Authors: Yongtai Cho, Yeon Soo Park, Yubin Lee, HyunJoo Lim, Ju-Young Shin, Soo-Heon Kwak,